Discontinuation of medication due to adverse events
It is very uncertain whether are disease‐modifying drugs for a first attack suggestive of… changes withdrawls or drug discontinuation due to adverse events during 24… compared with placebo? (very low certainty).
1 finding from 1 review
OR 2.43 [0.91, 6.49]
Studies not reported
Very low
Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.72 [0.45, 1.14]
Studies not reported
Low
Serious adverse events measured by plasma transfusion‐related complications within 24 hours № of participants: 21 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events Adverse events includes withdrawal and drop‐outs that could be clearly identified as due to an adverse event · patients with fibromyalgia
Acupuncture showed no clear difference in adverse events Adverse events includes withdrawal and drop‐outs that… compared with placebo or sham acupuncture (moderate certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Fexofenadine 120 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (1‐week intervention) (moderate certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Loratadine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · children with eczema
Cetirizine 0.5 mg/kg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (18‐month intervention) (moderate certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Cetirizine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review
Adverse events: Specific: Weight gain ‐ all doses of depot risperidone ‐ short term Spontaneous reporting by study participants · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific: Weight gain ‐ all doses of depot… compared with PLACEBO (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Raynaud's phenomenon
Calcium channel blockers showed no clear difference in number of withdrawals due to adverse events Number of participants… compared with placebo (low certainty).
1 finding from 1 review
Adverse events (control ‐ no treatment) · patients with first unprovoked seizure
Immediate treatment may leads to higher adverse events (control ‐ no treatment) compared with controls (low certainty).
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term Spontaneous reporting by study participants · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General: Severe adverse event ‐ any dose risperidone… compared with PLACEBO (very low certainty).
1 finding from 1 review
Serious adverse events Number of participants who died or withdrew and were hospitalized as a result of adverse effects of treatment · patients with Raynaud's phenomenon
1 finding from 1 review
Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events: 1 or more serious adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (e.g. the number of participants that died, or had arrhythmias, other heart rate disorders, or showed any signs of lidocaine toxicity) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events (common reactions to aromatherapy include skin rashes, dyspnoea, headache, cardiac arrhythmias, hypotension, hypertension or dizziness) · adults and children having any type of surgical procedure under general anaesthesia, regional anaesthesia or sedation, as hospital…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (common reactions to aromatherapy include skin rashes, dyspnoea, headache, cardiac arrhythmias, hypotension, hypertension or dizziness) · adults and children having any type of surgical procedure under general anaesthesia, regional anaesthesia or sedation, as hospital…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: including serious adverse events, vaso‐occlusive crisis, gastrointestinal disorder, headache or migraine, upper respiratory tract infection, rash · people with sickle cell disease
1 finding from 1 review
Dropouts, adverse events and deaths during intervention phase Numbers of dropouts, adverse events and deaths from all causes · people with stroke
tDCS showed no clear difference in secondary outcome measure: dropouts, adverse events and deaths… compared with any type of placebo or passive control intervention (moderate certainty).
1 finding from 1 review